证券日报网讯 12月10日，昊帆生物在互动平台回答投资者提问时表示，公司主要产品为多肽合成试 剂、通用型分子砌块等化学试剂，主要用于酰胺键的化学合成。公司经营会受到下游需求波动、价格波 动、行业竞争、产能布局等多方面因素影响，请投资者注意相关风险，理性判断。 （文章来源：证券日报） ...

证券日报网讯 12月10日，昊帆生物在互动平台回答投资者提问时表示，公司始终坚持以稳健经营、持 续创新和规范治理为基础，致力于为股东创造长期价值。在信息披露合规的前提下，公司积极通过多种 渠道加强与资本市场的沟通交流。公司将在市值管理方面持续优化。 （文章来源：证券日报） ...

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：司美格鲁肽核心专利将于明年三月份到期，对公司经 营是否会有积极影响？ 昊帆生物（301393.SZ）12月10日在投资者互动平台表示，公司主要产品为多肽合成试剂、通用型分子 砌块等化学试剂，主要用于酰胺键的化学合成。公司经营会受到下游需求波动、价格波动、行业竞争、 产能布局等多方面因素影响，请投资者注意相关风险，理性判断。 ...

（记者 王晓波） 昊帆生物（301393.SZ）12月10日在投资者互动平台表示，根据项目备案通知书，淮安昊帆新建年产 5130吨多肽合成试剂项目（一期）规划的生产规模为：年产缩合试剂2500吨、保护试剂800吨、绿色N 氨基化试剂100吨、手性消旋抑制试剂400吨、蛋白质试剂20吨、缩合活化助剂600吨、核苷酸试剂400 吨、多肽合成交联剂20吨、保护氨基酸290吨。本项目尚在建设中，未来可能根据市场需求变化、客户 开拓情况及公司战略调整进行动态优化，具有不确定性，请投资者注意相关风险。 每经AI快讯，有投资者在投资者互动平台提问：淮安昊帆生产基地建设项目，规划产品34种，设计产 能为每年5130吨。2026年先建设5个车间生产。请问淮安昊帆生产的产品分别是哪些？产能各自是多 少？ ...

（记者 王晓波） 每经AI快讯，有投资者在投资者互动平台提问：请问公司淮安项目主体建筑部分目前是否结顶？ 昊帆生物（301393.SZ）12月10日在投资者互动平台表示，淮安昊帆生产基地共规划10个生产车间，为 保障产能建设安全、快速、有序推进，公司拟分期建设生产线，计划在2026年先建设5个车间的生产线 并申请试生产，后续依据市场需求和产品布局开始规划和建设其他车间的生产线。目前该项目正在按照 既定规划有序推进。上述时间为管理层根据目前建设进展和现场情况所作的估计，项目实施面临各方面 不确定性因素，请投资者注意投资风险。为保证信息披露的公平性，公司将在定期报告和临时公告中披 露关于产能建设的重要进展。 ...

每经AI快讯，有投资者在投资者互动平台提问：司美格鲁肽核心专利将于明年三月份到期，对公司经 营是否会有积极影响？ （记者 王晓波） 昊帆生物（301393.SZ）12月10日在投资者互动平台表示，公司主要产品为多肽合成试剂、通用型分子 砌块等化学试剂，主要用于酰胺键的化学合成。公司经营会受到下游需求波动、价格波动、行业竞争、 产能布局等多方面因素影响，请投资者注意相关风险，理性判断。 ...

Market Overview - The biopharmaceutical sector experienced a decline of 1.72% on December 2, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3897.71, down 0.42%, while the Shenzhen Component Index closed at 13056.7, down 0.68% [1] Individual Stock Performance - Dongbao Bio (300239) closed at 5.80, up 1.05% with a trading volume of 93,700 shares and a transaction value of 53.99 million yuan [1] - Aopumai (688293) saw a significant drop of 8.01%, closing at 50.32 with a trading volume of 33,400 shares and a transaction value of 171 million yuan [2] - Other notable declines included Kanghong Pharmaceutical (002773) down 3.78% and Watson Bio (300142) down 3.17% [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 456 million yuan from institutional investors, while retail investors saw a net inflow of 270 million yuan [2] - Notable stocks with significant capital inflows included He Yuan Bio (688765) with a net inflow of 17.69 million yuan from institutional investors [3] - Conversely, stocks like Rongchang Bio (688331) and Shenzhou Cell (688520) also saw mixed capital flows, indicating varied investor sentiment [3]

Core Viewpoint - Haofan Bio (301393.SZ) announced changes in the use of raised funds and project completion timelines due to external policy changes and operational needs [1] Group 1: Fund Usage Changes - The project "Suzhou Haofan Bio Co., Ltd. 100kg/year peptide and protein reagent R&D and production and headquarters construction project (Phase I)" has reached a usable state, and the remaining funds will be used to supplement working capital [1] - The company plans to change the use of a total of 49,696.68 million yuan of raised funds from the "Anhui Haofan peptide reagent and pharmaceutical intermediates construction project" and "peptide and protein reagent R&D platform construction project" to the "Huaian Haofan production base construction project" [1] - The remaining funds after the changes will be used to supplement working capital, with the net amount being cash management income minus handling fees [1] Group 2: Project Completion and Timeline Adjustments - The "Anhui Haofan peptide reagent and pharmaceutical intermediates construction project" and "peptide and protein reagent R&D platform construction project" are proposed to be completed [1] - The timeline for the "Huaian Haofan production base construction project" is extended to December 2028 to ensure safe, rapid, and orderly capacity construction [1]

Core Points - Haofan Bio (301393.SZ) announced the approval of changes in the use of raised funds and the completion of certain fundraising projects during its board and supervisory meetings [1] Group 1: Fund Utilization Changes - The project "Suzhou Haofan Bio Co., Ltd. 100kg/year peptide and protein reagent R&D and production and headquarters construction project (Phase I)" has reached a state of intended use, and the remaining funds will be used to supplement working capital [1] - Due to external policy changes and the current operational needs, the company plans to change the use of a total of 49,696.68 million yuan of raised funds from the "Anhui Haofan peptide reagent and pharmaceutical intermediates construction project" and "peptide and protein reagent R&D platform construction project" to the "Huaian Haofan production base construction project" [1] - The "Anhui Haofan peptide reagent and pharmaceutical intermediates construction project" and "peptide and protein reagent R&D platform construction project" are proposed to be completed, with the remaining funds after the changes being used to supplement working capital [1] Group 2: Project Timeline Adjustments - To ensure the safe, rapid, and orderly advancement of capacity construction, the company has decided to phase the construction of the production line for the Huaian Haofan production base, extending the timeline to reach the intended use state until December 2028 [1]

Group 1 - The company announced the internal appointment changes, with Mr. Chen Yifan no longer serving as the head of the internal audit department, and Ms. Lu Liyan appointed as the new head [1] - For the year 2024, the company's revenue composition is entirely from the manufacturing of chemical raw materials and chemical products, accounting for 100.0% [1] - The current market capitalization of the company is 5.4 billion yuan [1]